Positive findings with exemestane/everolimus in the setting of advanced disease prompted the ongoing clinical testing of adjuvant everolimus in combination with anti-estrogen therapy for patients with high-risk early-stage ER+/HER2- breast cancer [12]; many such cases will have anti-estrogen-sensitive micrometastatic disease. The gene discussed is ESR1; the disease is breast cancer.